Third Rock Ventures and The Column Group Launch Nurix with $25.1 Million Financing to Target Key Regulatory Pathway

  Third Rock Ventures and The Column Group Launch Nurix with $25.1 Million
  Financing to Target Key Regulatory Pathway

 Company Brings Together Leaders in Ubiquitin-Proteasome Research to Discover
         and Develop Small Molecules with Broad Therapeutic Potential

Business Wire

SAN FRANCISCO & BOSTON -- May 22, 2014

Third Rock Ventures and The Column Group today announced the launch of Nurix,
Inc., a leader in discovering and developing therapies that modulate the
ubiquitin proteasome system (UPS), with a $25.1 million Series B financing
that follows a $6.2 million seed financing in 2012 led by the same investors.
The UPS is a regulatory pathway that directs protein degradation, a function
vital to the healthy life of a cell, and presents therapeutic opportunities in
multiple disease areas, including oncology. By taking a structural approach to
critical protein-protein interactions in the UPS that drive serious diseases,
Nurix is reaching therapeutic targets previously inaccessible to small
molecule drug discovery.

“Our understanding of the fundamental biology of the ubiquitin proteasome
system and its role in select cancers and other diseases has grown
significantly and continues to expand rapidly,” said Mark A. Goldsmith, M.D.,
Ph.D., interim chief executive officer of Nurix and partner of Third Rock
Ventures. “These advances have enabled Nurix to make breakthrough biological,
structural and chemical discoveries, positioning us to discover and develop
small molecules with the potential to make a dramatic difference for patients.
By combining a high-resolution molecular understanding of the ubiquitin
proteasome system with innovative approaches to modulating its components,
Nurix is making important progress in unlocking disease targets that have
largely eluded drug discovery efforts.”

Nurix was founded by internationally recognized experts in the UPS field:

  *John Kuriyan, Ph.D., Howard Hughes Medical Institute investigator and
    professor of molecular and cell biology and of chemistry, University of
    California, Berkeley, is an expert in the structural dynamics of ubiquitin
    ligases and other signaling complexes;
  *Michael Rapé, Ph.D., Howard Hughes Medical Institute investigator and
    professor of cell and developmental biology, University of California,
    Berkeley,  is a leader in the biology of ubiquitin-dependent cell cycle
    progression and carcinogenesis; and,
  *Arthur Weiss, M.D., Ph.D., Howard Hughes Medical Institute investigator
    and Ephraim P. Engleman distinguished professor, University of California
    San Francisco, is a pioneer in immunology and signal transduction.

“Nurix’s platform approach is applicable to a wide array of targets within the
ubiquitin proteasome system, and has the potential to enhance or inhibit
protein degradation,” said Mark Gallop, Ph.D., chief scientific officer of
Nurix. “This may allow us to promote the degradation of oncogenes or protect
naturally occurring tumor suppressors from being destroyed in the cell. We
believe the flexibility of this strategy combined with the ability to engineer
high selectivity for specific ligase-substrate interactions makes this a
powerful product engine with the potential to treat a number of serious
diseases.”

Nurix’s founding management team brings deep scientific expertise and
demonstrated success in drug discovery and development. Dr. Goldsmith was
formerly chief executive officer and is currently chairman of Constellation
Pharmaceuticals and has held a series of leadership positions in biotechnology
companies and academia. Dr. Gallop has 25 years of industry experience and
previously co-founded XenoPort, Inc. David Goeddel, Ph.D., managing partner of
The Column Group and a member of the Nurix board of directors, is a scientific
pioneer in the biotechnology field and was co-founder and chief executive
officer of Tularik.

About Nurix

Nurix, Inc. is a leader in discovering and developing therapies that modulate
the ubiquitin proteasome system (UPS). The UPS is a regulatory pathway that
directs protein degradation, a function vital to the healthy life of a cell,
and presents therapeutic opportunities in multiple disease areas, including
oncology. Nurix’s state-of–the-art product engine leverages a deep mechanistic
understanding of the UPS to deliver effective small molecule drug candidates
with the potential to make a dramatic difference for patients. Nurix was
founded by internationally recognized experts in the ubiquitin proteasome
field and is funded by leading life science investors, Third Rock Ventures and
The Column Group. The company is headquartered in San Francisco, California.
For more information, please visit www.nurix-inc.com.

About Third Rock Ventures

Third Rock Ventures is a leading healthcare venture firm focused on investing
and launching companies that make a difference in people’s lives. The Third
Rock team has a unique vision for ideating and building transformative
healthcare companies. Working closely with our strategic partners and
entrepreneurs, Third Rock has an extensive track record for managing the value
creation path to deliver exceptional performance. For more information, please
visit the firm’s website at www.thirdrockventures.com

About The Column Group

The Column Group (TCG) is a venture capital firm dedicated to creating a new
generation of breakthrough biotechnology companies. The TCG team deploys a
unique foundational approach to this challenge, partnering with exceptional
scientific founders and entrepreneurs at the earliest stages to transform an
innovative idea to a productive research and development company to a
potential industry leader capable of reshaping human health. For more
information, please visit www.thecolumngroup.net.

Contact:

Pure Communications, Inc.
Sheryl Seapy, 949-903-4750
sheryl@purecommunicationsinc.com
 
Press spacebar to pause and continue. Press esc to stop.